Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof‐of‐Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Issue 4 (30th November 2021)

• Record Type: Journal Article
• Authors: Shi, Jian; Xiao, Jingcheng; Wang, Xinwen; Jung, Sun Min; Bleske, Barry E.; Markowitz, John S.; Patrick, Kennerly S.; Zhu, Hao‐Jie
• Is Part Of: Clinical pharmacology & therapeutics. Volume 111:Issue 4(2022)
• Page Start: 878
• Page End: 885
• Publication Date: 2021-11-30
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2486
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Hepatic drug‐metabolizing enzymes (DMEs) play critical roles in determining the pharmacokinetics and pharmacodynamics of numerous therapeutic agents. As such, noninvasive biomarkers capable of predicting DME expression in the liver have the potential to be used to personalize pharmacotherapy and improve drug treatment outcomes. In the present study, we quantified carboxylesterase 1 (CES1) protein concentrations in plasma samples collected during a methylphenidate pharmacokinetics study. CES1 is a prominent hepatic enzyme responsible for the metabolism of many medications containing small ester moieties, including methylphenidate. The results revealed a significant inverse correlation between plasma CES1 protein concentrations and the area under the concentration‐time curves (AUCs) of plasma d‐methylphenidate ( P = 0.014, r = −0.617). In addition, when plasma CES1 protein levels were normalized to the plasma concentrations of 24 liver‐enriched proteins to account for potential interindividual differences in hepatic protein release rate, the correlation was further improved ( P = 0.003, r = −0.703), suggesting that plasma CES1 protein could explain ~ 50% of the variability in d‐methylphenidate AUCs in the study participants. A physiologically‐based pharmacokinetic modeling simulation revealed that the CES1‐based individualized dosing strategy might significantly reduce d‐methylphenidate exposure variability in pediatric patients relative to conventional trial and error fixed dosing regimens. This proof‐of‐concept study indicates that the plasma protein of a hepatic DME may serve as a biomarker for predicting its metabolic function and the pharmacokinetics of its substrate drugs.